Treatment-Resistant Depression: The Role of Electroconvulsive Therapy
DOI:
https://doi.org/10.12775/QS.2025.41.60326Keywords
electroconvulsive therapy, ECT, treatment resistant depression, TRDAbstract
Introduction and purpose: Depression remains the leading cause of disability worldwide, affecting the lives of nearly 300 million people. A particularly severe form of depression is treatment-resistant depression (TRD), which is associated with significant health, social, and economic problems. Its prevalence varies due to the lack of a unified definition. This paper reviews the efficacy and safety of electroconvulsive therapy (ECT) in the treatment of TRD.
Material and methods: A comprehensive search of the PubMed database was conducted to identify studies published between 2015 and 2025 that focused on electroconvulsive therapy in the context of treatment-resistant depression. The search strategy included keywords such as “electroconvulsive therapy,” “treatment-resistant depression”, “safety of electroconvulsive therapy.’’ Relevant articles were reviewed and evaluated based on the reported outcomes and the authors’ conclusions.
A brief description of the state of knowledge: Treatment-resistant depression (TRD) affects a great number of patients diagnosed with major depressive. Effective management of TRD requires appropriate pharmacotherapy, careful diagnostic evaluation and consideration of patient adherence. Electroconvulsive therapy (ECT) appears to be the most thoroughly researched and clinically effective method, particularly in severe cases and in populations at higher risk, such as older adults and pregnant women.
Conclusions: ECT remains one of the most effective treatment alternatives for TRD, especially in patients with severe symptoms or psychotic features. Choosing between these treatments should be guided by clinical context, patient characteristics, and personal preferences. Equally important is the need to continue working on breaking the stigma around mental health conditions and ECT, by raising awareawareness, educating people, and ensuring everyone has equal access to safe and effective treatment.
References
1. Ma C, Strelow B. Recognition and management of treatment-resistant depression. JAAPA. 2025;38(1):20-26. doi:10.1097/01.JAA.0000000000000163
2. McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. doi:10.1002/wps.21120
3. Alptekin FB, Inal-Azizoğlu S, Uysal A, Burhan HŞ, Güçlü O. Effects of different indications on electroconvulsive therapy. Efectos de las diferentes indicaciones sobre la terapia electroconvulsiva. Cir Cir. 2024;92(4):510-516. doi:10.24875/CIRU.23000625
4. Dominiak M, Antosik-Wójcińska AZ, Wojnar M, Mierzejewski P. Electroconvulsive Therapy and Age: Effectiveness, Safety and Tolerability in the Treatment of Major Depression among Patients under and over 65 Years of Age. Pharmaceuticals (Basel). 2021;14(6):582. Published 2021 Jun 18. doi:10.3390/ph14060582
5. Han KM, De Berardis D, Fornaro M, Kim YK. Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Prog Neuropsychopharmacol Biol Psychiatry. 2019;91:20-27. doi:10.1016/j.pnpbp.2018.03.022
6. Park MJ, Kim H, Kim EJ, et al. Recent Updates on Electro-Convulsive Therapy in Patients with Depression. Psychiatry Investig. 2021;18(1):1-10. doi:10.30773/pi.2020.0350
7. Espinoza RT, Kellner CH. Electroconvulsive Therapy. N Engl J Med. 2022;386(7):667-672. doi:10.1056/NEJMra2034954
8. Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023;388(25):2315-2325. doi:10.1056/NEJMoa2302399
9. Kirov G, Jauhar S, Sienaert P, Kellner CH, McLoughlin DM. Electroconvulsive therapy for depression: 80 years of progress. Br J Psychiatry. 2021;219(5):594-597. doi:10.1192/bjp.2021.37
10. Ekstrand J, Fattah C, Persson M, et al. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). Int J Neuropsychopharmacol. 2022;25(5):339-349. doi:10.1093/ijnp/pyab088
11. Ross EL, Zivin K, Maixner DF. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States. JAMA Psychiatry. 2018;75(7):713-722. doi:10.1001/jamapsychiatry.2018.0768
12. Rovers JJE, Vissers P, Loef D, et al. The impact of treatment resistance on outcome and course of electroconvulsive therapy in major depressive disorder. Acta Psychiatr Scand. 2023;147(6):570-580. doi:10.1111/acps.13550
13. Lex H, Nevers SW, Jensen EL, Ginsburg Y, Maixner DF, Mickey BJ. Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. J Affect Disord. 2021;291:135-139. doi:10.1016/j.jad.2021.05.012
14. Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362-367. doi:10.1016/j.jad.2018.04.016
15. Deng ZD, Robins PL, Regenold W, Rohde P, Dannhauer M, Lisanby SH. How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both?. Neuropsychopharmacology. 2024;49(1):150-162. doi:10.1038/s41386-023-01677-2
16. Antosik-Wójcińska A, Dominiak M, Goetz Z, et al. Analysis of the efficacy and safety of electroconvulsive therapy in elderly patients: a retrospective study in the Polish population. Analiza skuteczności i bezpieczeństwa zabiegów elektrowstrząsowych u pacjentów w wieku podeszłym: badanie retrospektywne w populacji polskiej. Psychiatr Pol. 2022;56(4):767-785. doi:10.12740/PP/OnlineFirst/132213
17. Cipolla S, Catapano P, Messina M, Pezzella P, Giordano GM. Safety of electroconvulsive therapy (ECT) in pregnancy: a systematic review of case reports and case series. Arch Womens Ment Health. 2024;27(2):157-178. doi:10.1007/s00737-023-01394-1
18. Coshal S, Jones K, Coverdale J, Livingston R. An Overview of Reviews on the Safety of Electroconvulsive Therapy Administered During Pregnancy. J Psychiatr Pract. 2019;25(1):2-6. doi:10.1097/PRA.0000000000000359
19. Bodnar A, Krzywotulski M, Lewandowska A, et al. Electroconvulsive therapy and cognitive functions in treatment-resistant depression. World J Biol Psychiatry. 2016;17(2):159-164. doi:10.3109/15622975.2015.1091501
20. Van de Velde N, Kappen M, Koster EHW, et al. Cognitive remediation following electroconvulsive therapy in patients with treatment resistant depression: randomized controlled trail of an intervention for relapse prevention - study protocol. BMC Psychiatry. 2020;20(1):453. Published 2020 Sep 16. doi:10.1186/s12888-020-02856-x
21. Napierała M, Bodnar A, Chlopocka-Wozniak M, Permoda-Osip A, Rybakowski J. Electroconvulsive therapy and autobiographical memory in patients with treatment-resistant depression. Terapia elektrowstrząsowa i pamięć autobiograficzna u pacjentów z depresją lekooporną. Psychiatr Pol. 2019;53(3):589-597. doi:10.12740/PP/85787
22. Jha MK, Wilkinson ST, Krishnan K, et al. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2417786. Published 2024 Jun 3. doi:10.1001/jamanetworkopen.2024.17786
23. Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis [published correction appears in JAMA Psychiatry. 2022 Dec 1;79(12):1241. doi: 10.1001/jamapsychiatry.2022.4135.]. JAMA Psychiatry. 2022;79(12):1162-1172. doi:10.1001/jamapsychiatry.2022.3352
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Magdalena Kupis, Monika Paszkowska, Patrycja Znamirowska, Klaudia Mularczyk, Łukasz Karaban, Anna Jakubiak, Joanna Miśkiewicz, Michał Borawski, Aleksandra Ciuła, Tadeusz Kuźnieców

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 130
Number of citations: 0